Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gold Fields Limited (GFI) vs Invesco Ltd. (IVZ) Price & Performance

Gold Fields LimitedTrade
Invesco Ltd.Trade

Price performance (Past 24H)

Key statistics

Gold Fields Limited vs Invesco Ltd. — how do they compare? Gold Fields Limited trades at $40.75 (market cap $36.07B), while Invesco Ltd. trades at $31.45 (market cap $13.85B). The key difference: Gold Fields Limited is far larger — about 2.6× Invesco Ltd.'s market cap, and Gold Fields Limited pays the higher dividend (5.76%). Which is the better fit depends on your goals.

GFIIVZ
Market Cap
$36.07B$13.85B
Sector
Basic MaterialsFinancials
52-Week High
$61.52$32.01
52-Week Low
$29.31$20.67
Enterprise Value
$37.51B$24.01B
Dividend Yield
5.76%2.74%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gold Fields Limited

Gold Fields (GFI) trades at $41.06, down slightly by 0.15% today. The stock shows strong fundamentals with robust profitability (40.76% net margin, 52.33% ROE) and attractive valuation (P/E 10.22, EV/EBITDA 5.92). Recent earnings were mixed with one beat and two misses, but 2025 projections indicate significant growth. Technical indicators show a bullish overall signal despite overbought RSI readings. Institutional interest remains strong with recent acquisitions by major funds.

The outlook for GFI appears positive with projected revenue growth to $8.8B and net income of $3.6B in 2025. Analyst consensus targets $52.00 (24% upside) with no sell ratings. Key risks include gold price volatility and operational challenges in mining operations. The combination of strong fundamentals, institutional support, and growth projections supports a constructive view for long-term investors.

Invesco Ltd.

Invesco (IVZ) trades at $31.58, down 0.5% today but near its 52-week high, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, with Q3 results pending. Revenue has grown to $6.38 billion in 2025, though net income remains negative. Analyst consensus is a $32.50 price target with a mix of Buy and Hold ratings, and the firm maintains a stable dividend payout.

The outlook for IVZ is cautiously optimistic, supported by strong assets under management and positive cash flow trends. However, profitability challenges and expense pressures pose risks. Upside potential hinges on earnings improvement and market sentiment, while downside risks include margin compression and competitive pressures in asset management.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gold Fields Limited

Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.

Read more on GFI

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ